Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan D Finn

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Blood Advances|March 3, 2021
Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variantsBenjamin J Samelson-Jones, Jonathan D Finn, Leslie J Raffini, et al.
The New England Journal of Medicine|October 23, 2009
X-linked thrombophilia with a mutant factor IX (factor IX Padua)Paolo Simioni, Daniela Tormene, Giulio Tognin, et al.
Blood|August 25, 2012
The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapyJonathan D Finn, Timothy C Nichols, Nikolaos Svoronos, et al.
Blood|January 9, 2015
AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and miceJulie M Crudele, Jonathan D Finn, Joshua I Siner, et al.
Journal of Virology|September 18, 2009
Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirusJonathan D Finn, Jennifer Bassett, James B Millar, et al.
Plos One|October 3, 2013
Characterization of naturally-occurring humoral immunity to AAV in sheepJoseph Tellez, Kim Van Vliet, Yu-Shan Tseng, et al.
Blood|September 30, 2010
Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapyJonathan D Finn, Margareth C Ozelo, Denise E Sabatino, et al.
Molecular Therapy. Methods & Clinical Development|June 16, 2025
Development of circular AAV cargos for targeted seamless insertion with large serine integrasesBrett J G Estes, Nisha Gandhi, Jessica R Von Stetina, et al.
The Journal of Clinical Investigation|May 14, 2009
Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectorsGary C Pien, Etiena Basner-Tschakarjan, Daniel J Hui, et al.
Blood|January 18, 2013
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cellsAshley T Martino, Etiena Basner-Tschakarjan, David M Markusic, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Blood Advances|March 3, 2021
Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variantsBenjamin J Samelson-Jones, Jonathan D Finn, Leslie J Raffini, et al.
The New England Journal of Medicine|October 23, 2009
X-linked thrombophilia with a mutant factor IX (factor IX Padua)Paolo Simioni, Daniela Tormene, Giulio Tognin, et al.
Blood|August 25, 2012
The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapyJonathan D Finn, Timothy C Nichols, Nikolaos Svoronos, et al.
Blood|January 9, 2015
AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and miceJulie M Crudele, Jonathan D Finn, Joshua I Siner, et al.
Journal of Virology|September 18, 2009
Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirusJonathan D Finn, Jennifer Bassett, James B Millar, et al.
Plos One|October 3, 2013
Characterization of naturally-occurring humoral immunity to AAV in sheepJoseph Tellez, Kim Van Vliet, Yu-Shan Tseng, et al.
Blood|September 30, 2010
Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapyJonathan D Finn, Margareth C Ozelo, Denise E Sabatino, et al.
Molecular Therapy. Methods & Clinical Development|June 16, 2025
Development of circular AAV cargos for targeted seamless insertion with large serine integrasesBrett J G Estes, Nisha Gandhi, Jessica R Von Stetina, et al.
The Journal of Clinical Investigation|May 14, 2009
Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectorsGary C Pien, Etiena Basner-Tschakarjan, Daniel J Hui, et al.
Blood|January 18, 2013
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cellsAshley T Martino, Etiena Basner-Tschakarjan, David M Markusic, et al.
Pageof 3